Figure 1
![Figure 1. Kaplan-Meier analysis of OS and PFS after 90Y-ibritumomab separated by group and stratum. (A) With a median follow-up time of 21.7 months, median survival was 21.4 months (95% confidence interval [CI] = 9.3, NC) for stratum AI, 22.4 months (95% CI = 17.6, NC) for stratum AII, and 4.6 months (95% CI = 3.0, NC) for group B. The follow-up period continued until 1 year after the last patient received 90Y-ibritumomab. (B) The median PFS was 5.9 months for stratum AI (95% CI = 3.3-15.0) and 3.5 months for stratum AII (95% CI = 2.8-10.2). In group B, the median PFS was 1.6 months (95% CI = 1.4-1.7). NC indicates not calculated.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/1/10.1182_blood-2007-01-068056/2/zh80130703460001.jpeg?Expires=1735830830&Signature=S6tdSQhcu2Zn~zr69t5ZlwvF2CVO2DgZ0vfOBn92j8rc44IjWfNTH2faocPoS-k2PlOUOr0Ls5HwS8FBDwEJ1arFHRSVdN~IQ~tobLRF9UuMPUAx2fICWQQ9xCYFdO2MQf~HQAXxRF~kel3lGTsYCd2~0F4PklBDcVC6a2csLnxO2rUrTRXYAR7kzte9gxNngWPT96PPO~F2-BsjQ6IB2Ih9H8TvT1YXj49OAdGGwnCGrdjqTRVWCUUYjnXHFYqH5aF7UyBEji0K-LJwl5-FcQ-QXXkqYU9l~bpEz3sDmNn6LaftWpmEsUKz-mZnCIx~m5nf1rkp~QC9IksTkuis5g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Kaplan-Meier analysis of OS and PFS after 90Y-ibritumomab separated by group and stratum. (A) With a median follow-up time of 21.7 months, median survival was 21.4 months (95% confidence interval [CI] = 9.3, NC) for stratum AI, 22.4 months (95% CI = 17.6, NC) for stratum AII, and 4.6 months (95% CI = 3.0, NC) for group B. The follow-up period continued until 1 year after the last patient received 90Y-ibritumomab. (B) The median PFS was 5.9 months for stratum AI (95% CI = 3.3-15.0) and 3.5 months for stratum AII (95% CI = 2.8-10.2). In group B, the median PFS was 1.6 months (95% CI = 1.4-1.7). NC indicates not calculated.
